2018/09/07 by Wojciech Jurczak, Krzysztof Chojnowski, Jiřı́ Mayer +6 · 30 citations
Medicine · #Platelet Disorders and Treatments #Blood groups and transfusion #Blood properties and coagulation
paper · pdf · doi:10.1111/bjh.15573
Summary Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6‐month, multicentre, randomised, double‐blind, parallel‐group Phase 3 study, with an open‐label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day) in adults with chronic immune thrombocytopenia ( ITP ) and a platelet count <30 × 10 9 /l (ClinicalTrials.gov identifier NCT 01438840). The primary endpoint was the cumulative number of weeks of platelet response (platelet count ≥50 × 10 9 /l) without rescue therapy for bleeding; secondary endpoints included platelet response rate at day 8 and reductions in the use of concomitant medications. Amongst the 49 patients randomised, avatrombopag ( N = 32) was superior to placebo ( N = 17) in the median cumulative number of weeks of platelet response (12·4 vs. 0·0 weeks, respectively; P < 0·0001). At day 8, a greater platelet response rate was also observed for patients treated with avatrombopag compared with placebo (65·63% vs. 0·0%; P < 0·0001), and use of concomitant ITP medications was also reduced amongst patients receiving avatrombopag. The safety profile of avatrombopag was consistent with Phase 2 studies; the most common adverse events were headache and contusion. Overall, avatrombopag was well tolerated and efficacious for the treatment of chronic ITP .